RxDoctor Payments Data

Keyvan Shirazi, MD

Internal Medicine · Encino, CANPI 1023033107

Payments from drug & device makers

$294in general payments, 2019–2025

Across 10 payments — averaging $29.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$145
  • Sun Pharmaceutical Industries Inc.$44
  • Sumitomo Pharma America, Inc.$31
  • Johnson & Johnson$20
  • Amarin Pharma, Inc.$16
  • Novartis$13
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$294 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,089,159
Medicare patients
875
Services billed
12,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate339$189,054
EliquisApixaban369$129,023
Metformin Er GastricMetformin Hcl72$90,351
Diclofenac Sodium257$80,164
OzempicSemaglutide54$67,942
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate58$54,188
JardianceEmpagliflozin79$53,717
VascepaIcosapent Ethyl170$46,012
Diclofenac Potassium17$42,003
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$39,189
InvokanaCanagliflozin45$33,149
FarxigaDapagliflozin Propanediol59$31,263
LinzessLinaclotide33$28,530
TrulicityDulaglutide28$26,266
MyrbetriqMirabegron65$25,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvokana, Xarelto$20$48,00396 claims
AstraZenecaFarxiga, Brilinta, Nexium$12$45,57089 claims
NovartisEntresto$13$14,76637 claims
Sumitomo Pharma America, Inc.Gemtesa$31$11,09225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →